Carl Zeiss Meditec : Präsentation Telefonkonferenz Quartalsmitteilung 2022/23

Carl Zeiss Meditec Group

Dr. Markus Weber, President and CEO

Justus Felix Wehmer, CFO

Aug 4, 2023

Agenda

01 9M 2022/23 at a Glance

02 Financial Performance

03 Highlights

04 Outlook

Carl Zeiss Meditec Group

Page 2

Strong revenue growth in 9M 2022/23 with continued high order backlog Ongoing strategic investment leads to reduced EBIT

9M 2022/23

9M 2021/22

9M 2022/23

9M 2021/22

9M 2022/23

9M 2021/22

	Revenue
€ 1,509.6 million	 FX-adj. revenue growth of +12.9%
 Positive revenue trend in both SBUs and all regions despite continuing supply chain
+13.3%
constraints and macroeconomic challenges
1,332.9
 Open orders of € 537m still at elevated levels
	EBIT
€ 244.9 million	 EBIT margin at 16.2% (PY 20.7%)
 Sequential gross margin improvement from Q1 through Q3 mainly due to recovery in
-11.2%
consumables business, Q3 gross profit and EBIT above PY's level
275.9
 Higher OpEx mainly arising from strategic investments in S&M and R&D for growth and
	innovation initiatives
	 Adj. EBIT margin at 16.8% (PY 21.2%)
	EPS
€ 2.29	 Higher earnings per share due to positive contribution from interest income, FX hedging
+7.3%
2.14

Carl Zeiss Meditec Group

Page 3

Agenda

01 9M 2022/23 at a Glance

02 Financial Performance

03 Highlights

04 Outlook

Carl Zeiss Meditec Group

Page 4

Ophthalmology

Topline growth primarily driven by accelerating deliveries of devices

Revenue

9M 2022/23		€ 1,152.3 million  FX-adj. revenue growth of +11.8%
			+12.2%	 Delivery of devices accelerated towards end of period - VISUMAX lead times still elevated
9M 2021/22	1,027.2	 Refractive treatment packs below PY's high levels (inventory build in China in H2 21/22)

9M 2022/23

9M 2021/22

	EBIT margin
14.0%	 EBIT margin decline affected by:
	Weaker product mix due to slower consumables growth and supply
-6.0 pps	−
20.0%		constraints in refractive business
−	Continued high level of strategic investment in research & development

and sales & marketing

MCS

Revenue Split

OPT	76.3%
of total revenue

Carl Zeiss Meditec Group

Page 5